Fundamental concepts in medicines safety
Authors:
- Faris El-DahiyatFEFaris El-Dahiyat
- Meriam AlomariMAMeriam Alomari
- Khawla Abu HammourKHKhawla Abu Hammour
- 9 October 2026
- book chapter
- Published by Elsevier
- p. 1-16
Abstract
No abstract availableThis publication has 40 references indexed in Scilit:
- Artificial intelligence and big data for pharmacovigilance and patient safetyJournal of Medicine, Surgery, and Public Health, 2024
- Targeted therapies and adverse drug reactions in oncology: the role of clinical pharmacist in pharmacovigilanceInternational Journal of Clinical Pharmacy, 2018
- EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health ProtectionDrug Safety, 2018
- Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS dataDiabetes/Metabolism Research and Reviews, 2017
- The US Food and Drug Administration’s Risk Evaluation and Mitigation Strategy (REMS) Program – Current Status and Future DirectionClinical Therapeutics, 2016
- Comparison Between Paediatric and Adult Suspected Adverse Drug Reactions Reported to the European Medicines Agency: Implications for PharmacovigilancePediatric Drugs, 2014
- Comparisons of Food and Drug Administration and European Medicines Agency Risk Management Implementation for Recent Pharmaceutical Approvals: Report of the International Society for Pharmacoeconomics and Outcomes Research Risk Benefit Management Working GroupValue in Health, 2012
- A basic study design for expedited safety signal evaluation based on electronic healthcare dataPharmacoepidemiology and Drug Safety, 2010
- The reporting odds ratio and its advantages over the proportional reporting ratioPharmacoepidemiology and Drug Safety, 2004
- A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactionsPharmacoepidemiology and Drug Safety, 2002